Gene delivery

Transfection Reagents and Equipment Market 2020-2024 | Need for Timely Disease Diagnosis to Boost Growth | Technavio

Wednesday, June 3, 2020 - 9:30pm

The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment.

Key Points: 
  • The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment.
  • Market estimates include pre- and post-COVID-19 impact on the Transfection Reagents and Equipment Market Download free sample report
    The market is fragmented, and the degree of fragmentation will accelerate during the forecast period.
  • The need for timely disease diagnosis has been instrumental in driving the growth of the market.
  • https://www.technavio.com/report/global-transfection-reagents-and-equipm...
    Transfection Reagents and Equipment Market 2020-2024: Segmentation
    Transfection Reagents and Equipment Market is segmented as below:

Insights on the Worldwide Viral Vector and Plasmid Manufacturing Industry to 2030 - Analysis and Forecast - ResearchAndMarkets.com

Wednesday, June 3, 2020 - 10:10am

According to this report the global viral vector and plasmid manufacturing market was valued at $1.16 billion in 2019 and is expected to be $5.86 billion in 2030.

Key Points: 
  • According to this report the global viral vector and plasmid manufacturing market was valued at $1.16 billion in 2019 and is expected to be $5.86 billion in 2030.
  • The viral vector and plasmid manufacturing market is expected to grow at a lower double-digit compound annual growth rate in the forecast period 2020-2030.
  • What are the major drivers, challenges, and opportunities of the global viral vector and plasmid manufacturing market?
  • Which are the key players of the global viral vector and plasmid manufacturing market, and what are their roles in the market?

LumaCyte’s Laser Force Cytology Accelerating Gene Therapy Production

Tuesday, June 2, 2020 - 1:28pm

LumaCyte recently collaborated with global cell and gene therapy leader, Catalent, where their joint teams uncovered valuable new capabilities in the monitoring of adeno-associated virus (AAV) production and infectivity, foundational precursors in the production of gene therapy products.

Key Points: 
  • LumaCyte recently collaborated with global cell and gene therapy leader, Catalent, where their joint teams uncovered valuable new capabilities in the monitoring of adeno-associated virus (AAV) production and infectivity, foundational precursors in the production of gene therapy products.
  • Gene therapy development and production is incredibly complex, where different cell lines and viral vectors can be used across the treatment manufacturing process.
  • Genetic methods such as ddPCR are commonly used to assess the production of gene therapy treatments, but results are slow and require significant skilled labor.
  • Catalent and LumaCyte are exploring the wide range of applications that Laser Force Cytology can offer the highly complex gene therapy development and manufacturing industry.

Study Demonstrating Role of IdeS in Enabling of Gene Therapy in the Presence of Neutralizing Anti-AAV Antibodies Published in Nature Medicine

Monday, June 1, 2020 - 4:00pm

One of the main challenges associated with AAV-mediated gene therapy is neutralizing antibodies that can impact the ability to administer gene therapy, saidFederico Mingozzi, Ph.D., chief scientific officer atSpark Therapeutics.

Key Points: 
  • One of the main challenges associated with AAV-mediated gene therapy is neutralizing antibodies that can impact the ability to administer gene therapy, saidFederico Mingozzi, Ph.D., chief scientific officer atSpark Therapeutics.
  • AAV-mediated gene therapy allows for the treatment of a growing number of diseases in patients today, however the presence of neutralizing anti-AAV antibodies can lead to limitations of this technology.
  • Furthermore, administration of AAV vectors systematically induces a neutralizing anti-AAV immune response, making gene therapy inefficient upon subsequent injections of AAV vectors.
  • Spark will assess and investigate the potential impact of the IdeS technology on its current gene therapy programs and potential applications in the future.

global market for viral vector and plasmid manufacturing is predicted to grow at a CAGR of 16.28% over the forecast period of 2020-2030

Thursday, May 28, 2020 - 7:20pm

What are the major drivers, challenges, and opportunities of the global viral vector and plasmid manufacturing market?

Key Points: 
  • What are the major drivers, challenges, and opportunities of the global viral vector and plasmid manufacturing market?
  • What are the key developmental strategies implemented by the key players of the global viral vector and plasmid manufacturing market to sustain the competition of the market?
  • What is the global market size for manufacturing plasmids and different types of viral vectors available in the global viral vector and plasmid manufacturing market in 2019?
  • What are the different disease areas where plasmids and viral vectors are employed in the global viral vector and plasmid manufacturing market?

Prevail Therapeutics to Present at The Jefferies Virtual Global Healthcare Conference

Tuesday, May 26, 2020 - 9:01pm

NEW YORK, May 26, 2020 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL) (Prevail or the Company), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases, today announced that Asa Abeliovich, M.D., Ph.D., Founder and Chief Executive Officer, will present a company overview at the upcoming Jefferies Virtual Global Healthcare Conference on Tuesday, June 2, 2020 at 3:30 p.m.

Key Points: 
  • NEW YORK, May 26, 2020 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL) (Prevail or the Company), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases, today announced that Asa Abeliovich, M.D., Ph.D., Founder and Chief Executive Officer, will present a company overview at the upcoming Jefferies Virtual Global Healthcare Conference on Tuesday, June 2, 2020 at 3:30 p.m.
  • A live webcast of the presentation will be available under Events and Presentations in the Investors & Media section of the company's website, www.prevailtherapeutics.com .
  • Prevail is a gene therapy company leveraging breakthroughs in human genetics with the goal of developing and commercializing disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases.
  • Prevail was founded by Dr. Asa Abeliovich in 2017, through a collaborative effort with The Silverstein Foundation for Parkinsons with GBA and OrbiMed, and is headquartered in New York, NY.

Research Report with COVID-19 Forecasts- Electroporation Instruments Market 2020-2024 | Demand for Monoclonal Antibodies to Boost Growth | Technavio

Saturday, May 23, 2020 - 4:00am

To learn more about the global trends impacting the future of market research, download a free sample: https://www.technavio.com/talk-to-us?report=IRTNTR40621

Key Points: 
  • To learn more about the global trends impacting the future of market research, download a free sample: https://www.technavio.com/talk-to-us?report=IRTNTR40621
    Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources.
  • Our electroporation instruments market report covers the following areas:
    This study identifies high demand for biopharmaceuticals as one of the prime reasons driving the electroporation instruments market growth during the next few years.
  • Backed with competitive intelligence and benchmarking, our research reports on the electroporation instruments market are designed to provide entry support, customer profile and M&As as well as go-to-market strategy support.
  • Register for a free trial today and gain instant access to 17,000+ market research reports.

The Non-viral Transfection Reagents and Systems Market is Projected to be Worth USD 1.4 Billion by 2030, Growing at a CAGR of 9.2%, Claims Roots Analysis

Thursday, May 14, 2020 - 4:15pm

LONDON, May 14, 2020 /PRNewswire/ -- Roots Analysis has announced the addition of " Non-Viral Transfection Reagents and Systems Market, 2020-2030 " report to its list of offerings.

Key Points: 
  • LONDON, May 14, 2020 /PRNewswire/ -- Roots Analysis has announced the addition of " Non-Viral Transfection Reagents and Systems Market, 2020-2030 " report to its list of offerings.
  • The growing demand for safe and effective genetically engineered ATMPs is likely to further propel the opportunity for non-viral transfection system developers.
  • To request a sample copy / brochure of this report, please visit this link
    Who are the leading players that offer non-viral transfection reagents and systems?
  • The USD 1.4 billion (by 2030) financial opportunity within the non-viral transfection reagents and systems market has been analyzed across the following segments:

The Non-viral Transfection Reagents and Systems Market is Projected to be Worth USD 1.4 Billion by 2030, Growing at a CAGR of 9.2%, Claims Roots Analysis

Thursday, May 14, 2020 - 4:15pm

The growing demand for safe and effective genetically engineered ATMPs is likely to further propel the opportunity for non-viral transfection system developers.

Key Points: 
  • The growing demand for safe and effective genetically engineered ATMPs is likely to further propel the opportunity for non-viral transfection system developers.
  • Further, it is worth noting that close to 50% of these trials were initiated in the last five years alone.
  • To request a sample copy / brochure of this report, please visit this link
    Who are the leading players that offer non-viral transfection reagents and systems?
  • The USD 1.4 billion (by 2030) financial opportunity within the non-viral transfection reagents and systems market has been analyzed across the following segments:

Otonomy and AGTC Present Preclinical Results Supporting Selection of Product Candidate for GJB2 Gene Therapy Hearing Loss Program

Tuesday, May 12, 2020 - 1:00pm

These results are being presented during the American Society of Gene & Cell Therapy (ASGCT) 23rd Annual Meeting being held virtually May 12-15, 2020.

Key Points: 
  • These results are being presented during the American Society of Gene & Cell Therapy (ASGCT) 23rd Annual Meeting being held virtually May 12-15, 2020.
  • Consistent gene expression can be observed in support cells throughout the cochlea for at least 12 weeks following a single local injection.
  • In October 2019, Otonomy and AGTC announced a strategic collaboration to co-develop and co-commercialize an AAV-based gene therapy to restore hearing in patients with sensorineural hearing loss caused by a mutation in the GJB2 gene.
  • The forward-looking statements in this press release are based on information available to Otonomy as of the date hereof.